[Case report: patient with central nervous system side effects due to lafutidine].
Department of Neurology, Iwate Prefectural Ninohe Hospital, Iwate, Japan.
Takahiko
T
Murata
Masahiro
M
Kawashima
Yasuo
Y
Terayama
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000628:therapy; D000077144:Clopidogrel; D006635:Histamine H2 Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010880:Piperidines; D011725:Pyridines; D064750:Rabeprazole; C076948:lafutidine; D000077144:Clopidogrel; D013988:Ticlopidine